Repurposing of anticancer drugs for the treatment of bacterial infections

Valerie W.C. Soo, Brian W. Kwan, Héctor Quezada, Israel Castillo-Juárez, Berenice Pérez-Eretza, Silvia Julieta García-Contreras, Mariano Martínez-Vázquez, Thomas Keith Wood, Rodolfo García-Contreras

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Despite the fact that bacterial infections are one of the leading causes of death worldwide and that mortality rates are increasing at alarming rates, no new antibiotics have been produced by the pharmaceutical industry in more than a decade. The situation is so dire that the World Health Organization warned that we may enter a “post-antibiotic era” within this century; accordingly, bacteria resistant against all known antibiotics are becoming common and already producing untreatable infections. Although several novel approaches to combat bacterial infections have been proposed, they have yet to be implemented in clinical practice. Hence, we propose that a more plausible and faster approach is the utilization of drugs originally developed for other purposes besides antimicrobial activity. Among these are some anticancer molecules proven effective in vitro for eliminating recalcitrant, multidrug tolerant bacteria; some of which also protect animals from infections and recently are undergoing clinical trials. In this review, we highlight the similarities between cancer cells/tumors and bacterial infections, and present evidence that supports the utilization of some anticancer drugs, including 5-fluorouracil (5-FU), gallium (Ga) compounds, and mitomycin C, as antibacterials. Each of these drugs has some promising properties such as broad activity (all three compounds), dual antibiotic and antivirulence properties (5-FU), efficacy against multidrug resistant strains (Ga), and the ability to kill metabolically dormant persister cells which cause chronic infections (mitomycin C).

Original languageEnglish (US)
Pages (from-to)1157-1176
Number of pages20
JournalCurrent Topics in Medicinal Chemistry
Volume17
Issue number10
DOIs
StatePublished - Apr 1 2017

Fingerprint

Drug Repositioning
Bacterial Infections
Anti-Bacterial Agents
Gallium
Mitomycin
Fluorouracil
Infection
Drug Utilization
Bacteria
Drug Industry
Pharmaceutical Preparations
Cause of Death
Neoplasms
Clinical Trials
Mortality

All Science Journal Classification (ASJC) codes

  • Drug Discovery

Cite this

Soo, V. W. C., Kwan, B. W., Quezada, H., Castillo-Juárez, I., Pérez-Eretza, B., García-Contreras, S. J., ... García-Contreras, R. (2017). Repurposing of anticancer drugs for the treatment of bacterial infections. Current Topics in Medicinal Chemistry, 17(10), 1157-1176. https://doi.org/10.2174/1568026616666160930131737
Soo, Valerie W.C. ; Kwan, Brian W. ; Quezada, Héctor ; Castillo-Juárez, Israel ; Pérez-Eretza, Berenice ; García-Contreras, Silvia Julieta ; Martínez-Vázquez, Mariano ; Wood, Thomas Keith ; García-Contreras, Rodolfo. / Repurposing of anticancer drugs for the treatment of bacterial infections. In: Current Topics in Medicinal Chemistry. 2017 ; Vol. 17, No. 10. pp. 1157-1176.
@article{c3b1e59a45384eee9e0e5a5feec51d58,
title = "Repurposing of anticancer drugs for the treatment of bacterial infections",
abstract = "Despite the fact that bacterial infections are one of the leading causes of death worldwide and that mortality rates are increasing at alarming rates, no new antibiotics have been produced by the pharmaceutical industry in more than a decade. The situation is so dire that the World Health Organization warned that we may enter a “post-antibiotic era” within this century; accordingly, bacteria resistant against all known antibiotics are becoming common and already producing untreatable infections. Although several novel approaches to combat bacterial infections have been proposed, they have yet to be implemented in clinical practice. Hence, we propose that a more plausible and faster approach is the utilization of drugs originally developed for other purposes besides antimicrobial activity. Among these are some anticancer molecules proven effective in vitro for eliminating recalcitrant, multidrug tolerant bacteria; some of which also protect animals from infections and recently are undergoing clinical trials. In this review, we highlight the similarities between cancer cells/tumors and bacterial infections, and present evidence that supports the utilization of some anticancer drugs, including 5-fluorouracil (5-FU), gallium (Ga) compounds, and mitomycin C, as antibacterials. Each of these drugs has some promising properties such as broad activity (all three compounds), dual antibiotic and antivirulence properties (5-FU), efficacy against multidrug resistant strains (Ga), and the ability to kill metabolically dormant persister cells which cause chronic infections (mitomycin C).",
author = "Soo, {Valerie W.C.} and Kwan, {Brian W.} and H{\'e}ctor Quezada and Israel Castillo-Ju{\'a}rez and Berenice P{\'e}rez-Eretza and Garc{\'i}a-Contreras, {Silvia Julieta} and Mariano Mart{\'i}nez-V{\'a}zquez and Wood, {Thomas Keith} and Rodolfo Garc{\'i}a-Contreras",
year = "2017",
month = "4",
day = "1",
doi = "10.2174/1568026616666160930131737",
language = "English (US)",
volume = "17",
pages = "1157--1176",
journal = "Current Topics in Medicinal Chemistry",
issn = "1568-0266",
publisher = "Bentham Science Publishers B.V.",
number = "10",

}

Soo, VWC, Kwan, BW, Quezada, H, Castillo-Juárez, I, Pérez-Eretza, B, García-Contreras, SJ, Martínez-Vázquez, M, Wood, TK & García-Contreras, R 2017, 'Repurposing of anticancer drugs for the treatment of bacterial infections', Current Topics in Medicinal Chemistry, vol. 17, no. 10, pp. 1157-1176. https://doi.org/10.2174/1568026616666160930131737

Repurposing of anticancer drugs for the treatment of bacterial infections. / Soo, Valerie W.C.; Kwan, Brian W.; Quezada, Héctor; Castillo-Juárez, Israel; Pérez-Eretza, Berenice; García-Contreras, Silvia Julieta; Martínez-Vázquez, Mariano; Wood, Thomas Keith; García-Contreras, Rodolfo.

In: Current Topics in Medicinal Chemistry, Vol. 17, No. 10, 01.04.2017, p. 1157-1176.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Repurposing of anticancer drugs for the treatment of bacterial infections

AU - Soo, Valerie W.C.

AU - Kwan, Brian W.

AU - Quezada, Héctor

AU - Castillo-Juárez, Israel

AU - Pérez-Eretza, Berenice

AU - García-Contreras, Silvia Julieta

AU - Martínez-Vázquez, Mariano

AU - Wood, Thomas Keith

AU - García-Contreras, Rodolfo

PY - 2017/4/1

Y1 - 2017/4/1

N2 - Despite the fact that bacterial infections are one of the leading causes of death worldwide and that mortality rates are increasing at alarming rates, no new antibiotics have been produced by the pharmaceutical industry in more than a decade. The situation is so dire that the World Health Organization warned that we may enter a “post-antibiotic era” within this century; accordingly, bacteria resistant against all known antibiotics are becoming common and already producing untreatable infections. Although several novel approaches to combat bacterial infections have been proposed, they have yet to be implemented in clinical practice. Hence, we propose that a more plausible and faster approach is the utilization of drugs originally developed for other purposes besides antimicrobial activity. Among these are some anticancer molecules proven effective in vitro for eliminating recalcitrant, multidrug tolerant bacteria; some of which also protect animals from infections and recently are undergoing clinical trials. In this review, we highlight the similarities between cancer cells/tumors and bacterial infections, and present evidence that supports the utilization of some anticancer drugs, including 5-fluorouracil (5-FU), gallium (Ga) compounds, and mitomycin C, as antibacterials. Each of these drugs has some promising properties such as broad activity (all three compounds), dual antibiotic and antivirulence properties (5-FU), efficacy against multidrug resistant strains (Ga), and the ability to kill metabolically dormant persister cells which cause chronic infections (mitomycin C).

AB - Despite the fact that bacterial infections are one of the leading causes of death worldwide and that mortality rates are increasing at alarming rates, no new antibiotics have been produced by the pharmaceutical industry in more than a decade. The situation is so dire that the World Health Organization warned that we may enter a “post-antibiotic era” within this century; accordingly, bacteria resistant against all known antibiotics are becoming common and already producing untreatable infections. Although several novel approaches to combat bacterial infections have been proposed, they have yet to be implemented in clinical practice. Hence, we propose that a more plausible and faster approach is the utilization of drugs originally developed for other purposes besides antimicrobial activity. Among these are some anticancer molecules proven effective in vitro for eliminating recalcitrant, multidrug tolerant bacteria; some of which also protect animals from infections and recently are undergoing clinical trials. In this review, we highlight the similarities between cancer cells/tumors and bacterial infections, and present evidence that supports the utilization of some anticancer drugs, including 5-fluorouracil (5-FU), gallium (Ga) compounds, and mitomycin C, as antibacterials. Each of these drugs has some promising properties such as broad activity (all three compounds), dual antibiotic and antivirulence properties (5-FU), efficacy against multidrug resistant strains (Ga), and the ability to kill metabolically dormant persister cells which cause chronic infections (mitomycin C).

UR - http://www.scopus.com/inward/record.url?scp=85015674221&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85015674221&partnerID=8YFLogxK

U2 - 10.2174/1568026616666160930131737

DO - 10.2174/1568026616666160930131737

M3 - Article

VL - 17

SP - 1157

EP - 1176

JO - Current Topics in Medicinal Chemistry

JF - Current Topics in Medicinal Chemistry

SN - 1568-0266

IS - 10

ER -

Soo VWC, Kwan BW, Quezada H, Castillo-Juárez I, Pérez-Eretza B, García-Contreras SJ et al. Repurposing of anticancer drugs for the treatment of bacterial infections. Current Topics in Medicinal Chemistry. 2017 Apr 1;17(10):1157-1176. https://doi.org/10.2174/1568026616666160930131737